$Esperion Therapeutics (ESPR.US)$ HOT NEWS ON OBESITY STUDY ...
HOT NEWS ON OBESITY STUDY
Esperion (Nasdaq: ESPR) presented positive results from the CLEAR Outcomes trial at the 2024 American College of Cardiology’s Annual Scientific Sessions. Patients with obesity on NEXLETOL had a 23% lower risk of MACE-4 compared to placebo. The trial highlighted benefits in women and Hispanic/Latinx patients, emphasizing the importance of early LDL-C lowering for reducing cardiovascular events.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
453Followers
65Following
2882Visitors
Follow